BridgeBio Pharma, Inc. (BBIO) /
The cash flow of BridgeBio Pharma, Inc. over the past 9 years
Chart BridgeBio Pharma, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2017–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, BridgeBio Pharma, Inc.'s operating cash flow was -$445.91M and its capital expenditures $1.1M, leaving free cash flow of -$447.01M. Free cash flow was below zero in all 9 years shown. It ranged from -$529.03M in fiscal 2023 to -$40.95M in fiscal 2017. Capital expenditures were highest in fiscal 2021, at $13.25M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$445.91M | $1.1M | -$447.01M |
| 2024ended Dec 31, 2024 | -$520.73M | $933K | -$521.66M |
| 2023ended Dec 31, 2023 | -$527.72M | $1.31M | -$529.03M |
| 2022ended Dec 31, 2022 | -$419.49M | $4.82M | -$424.31M |
| 2021ended Dec 31, 2021 | -$497.93M | $13.25M | -$511.18M |
| 2020ended Dec 31, 2020 | -$399.71M | $7.52M | -$407.23M |
| 2019ended Dec 31, 2019 | -$253.59M | $2.64M | -$256.23M |
| 2018ended Dec 31, 2018 | -$136.64M | $2.18M | -$138.82M |
| 2017ended Dec 31, 2017 | -$40.49M | $464K | -$40.95M |
Fiscal years as BridgeBio Pharma, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on BridgeBio Pharma, Inc.
- The revenue of BridgeBio Pharma, Inc.
- The profitability of BridgeBio Pharma, Inc.
- The debt of BridgeBio Pharma, Inc.
- All of BridgeBio Pharma, Inc.'s financials, charted
Companies of a similar size
- TXTTextron Inc.
- ARCCAres Capital Corp
- LSCCLATTICE SEMICONDUCTOR CORP
- DOCHealthpeak Properties, Inc.
- MTZMASTEC INC
Not investment advice. This page shows what BridgeBio Pharma, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.